Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
11:25am, Tuesday, 08'th Aug 2023
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.55 per share a year ago.
EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc
08:34pm, Thursday, 27'th Jul 2023
San Francisco-based investment firm, EcoR1 Capital, LLC (Trades, Portfolio), recently executed a significant transaction involving the acquisition of shares in Mersana Therapeutics Inc. This article p
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
12:20pm, Friday, 16'th Jun 2023
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.
Mersana Therapeutics shares tank as FDA puts ovarian cancer drug trials on partial hold
10:18am, Thursday, 15'th Jun 2023
Mersana Therapeutics (NASDAQ:MRSN) stock plummeted more than 60% on Thursday after the clinical-stage biopharmaceutical company announced that the Food and Drug Administration (FDA) has issued a parti
US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold
08:03am, Thursday, 15'th Jun 2023
Mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its ovarian cancer drug studies and paused patient enrollment, citing safety co
7 Stocks to Buy for 200% Returns This Year
06:00am, Tuesday, 13'th Jun 2023
In order for a stock to provide 200% returns it needs to at least triple in price. That's the kind of shares we'll be discussing below.
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
08:00am, Wednesday, 03'rd May 2023
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
08:00am, Tuesday, 02'nd May 2023
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight
05:20pm, Monday, 03'rd Apr 2023
Concerns related to safety risks around ILD/pneumonitis are overblown in a disease of high unmet needs. I believe clinical benefits outweigh potential safety overhang, and key studies have put in the
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
11:30am, Monday, 13'th Mar 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod
Mersana Therapeutics Provides Statement About SVB
12:10am, Saturday, 11'th Mar 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Friday, 03'rd Mar 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Call Transcript
10:50am, Tuesday, 28'th Feb 2023
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Jason Fredette - SVP, IR and Corporate Communications Anna Protopapas - Pre
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
01:00pm, Tuesday, 21'st Feb 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
08:00am, Tuesday, 21'st Feb 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
